Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial.
Yong-Jun WangJiejie LiClaiborne JohnstonGraeme J HankeyJ Donald EastonXia MengFu-Dong ShiYilong WangXing-Quan ZhaoZixiao LiLiping LiuHong-Qiu GuYong JiangAnxin WangYue-Song PanJing JingSiying NiuHao LiPublished in: International journal of stroke : official journal of the International Stroke Society (2023)
The CHANCE-3 trial will evaluate the efficacy and safety of colchicine for secondary prevention after stroke and TIA.Trial registry name: Colchicine in High-risk Patients With Acute MiNor-to-moderate IschemiC Stroke or TransiEnt Ischemic Attack (CHANCE-3); URL: https://clinicaltrials.gov/ct2/show/NCT05439356?cond=CHANCE-3&draw=2&rank=1; Registration number: NCT05439356.
Keyphrases
- phase iii
- double blind
- phase ii
- cerebral ischemia
- study protocol
- clinical trial
- placebo controlled
- open label
- atrial fibrillation
- high intensity
- randomized controlled trial
- computed tomography
- ischemia reperfusion injury
- subarachnoid hemorrhage
- magnetic resonance imaging
- dual energy
- cross sectional
- magnetic resonance
- positron emission tomography